MAMahmoud Manouchehri Amoli

Mahmoud Manouchehri Amoli

*This is an algorithmically generated author record based on publicly available information.

Mahmoud Manouchehri Amoli has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Bassam Dahman

    Department of Health Policy Virginia Commonwealth University Richmond Virginia USA

    2 shared publications
  • Peter J. Cunningham

    Department of Health Policy, School of Public Health Virginia Commonwealth University Richmond Virginia USA

    2 shared publications
  • Atousa Mortazavi Milani

    Clinical Research Development Unit of Imam Khomeini Hospital, Mazandaran University of Medical Science, Sari, Iran

    1 shared publication
  • Bassam Dahman

    Department of Health Policy, School of Public Health, Virginia Commonwealth University, Richmond, VA

    1 shared publication
  • Bassam Dahman

    Section of Gastroenterology and Hepatology, Miami VA Health System, Miami, Florida, USA

    1 shared publication
  • Binu V. John

    Division of Gastroenterology and Hepatology, VA Medical Center University of Miami Miami Florida USA

    1 shared publication

Latest Publications

  • Open Access

    MIPS Under Scrutiny: Exploring the Association Between Providers With Fraudulent Practices and Quality Metrics Within MACRA's Framework

    by Mahmoud Manouchehri Amoli, Peter J. Cunningham, Brian Cassel, Nathan W. Carroll, Bassam Dahman

    Importance: Identifying how fraudulent practices affect quality performance metrics is crucial for enhancing healthcare delivery and maintaining the integrity of the Medicare system.Objective: To examine the association between fraud and abuse perpetrator providers (FAPs) and their performance on quality metrics within the Merit‐Based Incentive Payment System (MIPS) under the Medicare Access and CHIP Reauthorization Act (MACRA).Design: A retrospective observational study using exact matching and propensity score matching to balance comparison groups.Setting: Analysis of Medicare Quality Payment Program (QPP) data from 2017 to 2021.Participants: A total of 12,364 physician‐year observations, including 1300 provider‐year level FAPs identified between 2020 and 2023 and 11,064 matched non‐FAPs.Exposures: Provider status as fraud and abuse perpetrators based on inclusion in the List of Excluded Individuals and Entities from the Office of Inspector General.Main Outcomes and Measures: MIPS scores across key categories: Final score, Quality score, Promoting Interoperability (PI) score, Improvement Activities (IA) score, and Cost score.Results: FAPs scored significantly lower than non‐FAPs in Final score, Quality score, PI score, and IA score (all p < 0.05). The negative impact of FAP status was more pronounced among individual practitioners, while FAPs participating in Advanced Alternative Payment Models exhibited higher scores on certain metrics. No significant differences were observed in Cost scores between FAPs and non‐FAPs.Conclusions and Relevance: Fraudulent practices are associated with lower performance on quality‐related metrics under MACRA's MIPS framework, particularly among individual practitioners. While lower quality scores align with expectations for providers committing fraud, the absence of significant differences in Cost scores highlights potential shortcomings in the MIPS scoring system, suggesting that cost metrics may not be sufficiently sensitive to fraudulent practices. These findings underscore the need for continuous refinement of both quality and cost measures to enhance the integrity and effectiveness of healthcare delivery.


  • The Effect of Medicaid Expansion on Care for Patients With Diabetes by Primary Care Provider Supply

    by Mahmoud Manouchehri Amoli, Peter J. Cunningham, Masoudeh Masoud Bahnamiri, Mohammad Javad Najafi, Atousa Mortazavi Milani, Bassam Dahman

    Objective: We examined whether Medicaid expansion led to improvements in health, access, and preventive care for low-income adults with diabetes, varying by primary care provider (PCP) supply. Research Design and Methods: Using 2011–2021 Behavioral Risk Factor Surveillance System data and a difference-in-differences approach, we compared outcomes before and after expansion in states classified by PCP supply. The sample included 85,375 adults aged 18–64 with incomes below 138% of the federal poverty level and a diabetes diagnosis. Outcomes were self-reported: health insurance coverage, personal doctor, cost-related delays in care, routine checkups, flu shots, and days with poor mental or physical health. Results: Across all states, Medicaid expansion was associated with a 3.2 and 3.5 percentage-point (pp) increase in insurance coverage and checkup visits, respectively. High-PCP-supply states realized larger gains in coverage (6.4 pp) as well as improvements in routine checkups (3.3 pp) and flu vaccination (3.5 pp). They also showed a reduction of nearly one day of poor mental health per month. In contrast, low-PCP-supply states experienced a marginally significant increase in poor mental health days. Conclusions: Medicaid expansion improved coverage, preventive care, and mental health outcomes for low-income adults with diabetes, with more pronounced benefits in high-PCP-supply states. These findings underscore the importance of adequate PCP capacity to optimize the impact of coverage expansions in managing chronic conditions such as diabetes. Policymakers aiming to enhance care for vulnerable patients with diabetes should consider investing in primary care infrastructure alongside coverage expansions.

  • Open Access

    Navigating New Waters: How Did MACRA 2015 Transform Practices Among Medicare Part B Physicians?

    by Mahmoud Manouchehri Amoli, Bassam Dahman

    Objectives: To assess whether physicians participating in the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) exhibit different billing behaviors and practice patterns compared to non‐participating physicians after MACRA implementation.Study Setting and Design: A quasi‐experimental staggered difference‐in‐difference design was used to compare pre‐and post‐MACRA changes among participants and non‐participants from 2013 to 2021. Primary outcomes included annual submitted charges, annual Medicare payments, and charge‐to‐payment ratios. Secondary outcomes were average charges and payments per beneficiary, total services, and the number of beneficiaries served.Data Sources and Analytic Sample: The study analyzed secondary data from Centers for Medicare & Medicaid Services (CMS) Medicare Fee‐For‐Service Provider Utilization and Payment Data (2013–2021), providing outcome measures and control variables; Quality Payment Program (QPP) Experience Reports (2017–2021), the National Plan and Provider Enumeration System, and Medicare Geographic Variation Public Use File. The analytic sample included 4,924,118 physician‐year observations (749,129 unique physicians), with 50.2% participating in MACRA.Principal Findings: MACRA participation was associated with significant annual increases of $36,677 (95% CI: 28,918, 44,436) in total submitted charges and $9164 (95% CI: 7288, 11,041) in total Medicare payments compared to non‐participation. However, these increases appeared primarily driven by a substantial increase in the total number of Medicare beneficiaries served per physician (29.77 beneficiaries; 95% CI: 20.75, 32.79) rather than by increases in spending per beneficiary, which were modest (average payment increase per beneficiary of $2.10; 95% CI: 0.22, 3.97). The charge‐to‐payment ratio decreased by 0.04 percentage points (95% CI: −0.08, −0.00) among MACRA participants, suggesting potential improvements in billing efficiency.Conclusions: MACRA participation is associated with increased billing and payment among Medicare Part B physicians, primarily driven by physicians treating a greater number of Medicare beneficiaries. However, modest changes in per‐beneficiary spending suggest limited changes in care intensity. Further research is needed to explore factors influencing patient volumes and payer mix under MACRA.


  • Open Access

    Hepatitis delta testing trends in a US national cohort: An analysis of patient and provider-level predictive factors

    by Binu V. John, Mahmoud Manouchehri Amoli, Donna M. Evon, Robert Wong, Bassam Dahman

    Background: The low prevalence of HDV infection in the United States could be attributed to insufficient testing rate, which can result in an underestimation of the true burden of HDV. The primary objective of this study is to quantify the prevalence of and factors associated with HDV antibody (anti-HDV) or RNA testing, among participants with positive HBsAg in the Veterans Health Administration (VHA). Methods: We conducted a retrospective cohort study of participants who tested positive for HBsAg between January 2000 and December 2022 within the VHA. We identified those who were tested for HDV, and patient and provider-level factors associated with HDV testing. Results: Of 41,658 participants with positive HBsAg who had follow-up, 4438 (10.7%) were tested at least once for HDV, of which 135 (3.0%) were positive. Participants in the Northeast (adjusted odds ratio [aOR]: 1.30, 95% CI: 1.17–1.44, ppppp=0.001), participants who were HCV antibody–positive (aOR: 0.89, 95% CI: 0.81–0.99, p=0.03), and participants who were HIV-positive (aOR: 0.80, 95% CI: 0.71–0.90, p<0.001) were less likely to be tested for HDV. Conclusions: HDV screening rates in the VHA remain low overall. Participants who are Black, living in the Midwest, patients who are HIV-positive, and patients who are HCV-positive are less likely to be tested for HDV. These results suggest that risk-based screening strategies are ineffective in the VHA and highlight the need for refining testing strategies to increase HDV screening rates.